Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
NCT ID: NCT00807196
Last Updated: 2008-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2008-09-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T
Rituximab
250mg/m2 day -21 and day -14 of preparative regimen
90Y ibritumomab tiuxetan (Zevalin)
0.4 mCi/kg IV on day -14 of preparative regimen
Cyclophosphamide
300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Fludarabine
30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Non myeloablative allogeneic stem cell transplantation
Blood stem cell infusion on day 0
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab
250mg/m2 day -21 and day -14 of preparative regimen
90Y ibritumomab tiuxetan (Zevalin)
0.4 mCi/kg IV on day -14 of preparative regimen
Cyclophosphamide
300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Fludarabine
30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Non myeloablative allogeneic stem cell transplantation
Blood stem cell infusion on day 0
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age 18 to 65 years. Patients between age 66 and 69 may be enrolled if judged to be in excellent physical condition as per treating physician and study investigator and based on institutional practice.
2. Diagnosis of Non-Hodgkin lymphoma, follicular, marginal zone, small lymphocytic lymphoma, mantle cell lymphoma or transformed from an indolent NHL to aggressive histology disease lymphoma as defined by the World Health Organization.
3. Disease relapsed after, refractory or failing to achieve a PR after two or more cycles of intensive salvage chemotherapy (R-ESHAP or other) or disease relapsed after autologous stem cell transplantation. Poor partial response is defined as less than 50% reduction of tumor size. Salvage chemotherapy has to be administered after either 1st, 2nd or 3rd relapse
4. Disease expressing the CD 20 antigen
5. ECOG performance status 0-2
6. Judged to be able to tolerate NST and Zevalin treatment based on institutional criteria.
7. Signed written informed consent
8. At least one fully HLA matched sibling without evident contraindications to the donation procedures and willing to sign consent for donation
Exclusion Criteria
1. Abnormal renal function (creatinine \> 1.5 x upper limit of normal (ULN)
2. Abnormal hepatic function (bilirubin \> 2 x ULN, ALT/AST\>2x ULN)
3. Cardiac ejection fraction \<40% and/or other significant cardiac compromise
4. Severe defects in pulmonary function tests or receiving continuous oxygen
5. Severe concurrent illness, such as symptomatic congestive heart failure, severe arrhythmias, uncontrolled hypertension, diabetes, severe neurologic or psychiatric disorder or known HIV positive
6. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1) that may impact on patients life expectancy or any cancer curatively treated \< 3 years prior to study entry.
7. History of prior allogeneic bone marrow transplant
8. Evidence of active hepatitis B or C infection or positivity for hepatitis-B surface antigen
9. Known type 1 hypersensitivity or anaphylactic proteins to any component of the Zevalin therapy or a history or presence of human anti-mouse antibodies (HAMA)
10. A female patient who is pregnant or breast feeding and an adult of reproductive potential who is not employing an effective method of birth control during the study.
11. CNS lymphoma
12. Ongoing confirmed or suspected significant infection
13. Prior treatment with radioimmunotherapy
14. Other condition preventing participation in standard NST
15. No fully matched sibling donor
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Maisonneuve-Rosemont Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hopital Maisonneuve-Rosemont
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Kiss, MD
Role: PRINCIPAL_INVESTIGATOR
Maisonneuve-Rosemont Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Thomas Kiss, MD
Role: primary
Dominique Beaupré, BSc nursing
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZEV0701
Identifier Type: -
Identifier Source: org_study_id